- Home
- PTGX vs ASTH Comparison
PTGX vs ASTH Comparison
Compare PTGX & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- ASTH
- Stock Information
- Founded
- PTGX 2006
- ASTH 1994
- Country
- PTGX United States
- ASTH United States
- Employees
- PTGX N/A
- ASTH N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- ASTH Professional Services
- Sector
- PTGX Health Care
- ASTH Consumer Discretionary
- Exchange
- PTGX Nasdaq
- ASTH Nasdaq
- Market Cap
- PTGX 3.7B
- ASTH 1.3B
- IPO Year
- PTGX 2016
- ASTH N/A
- Fundamental
- Price
- PTGX $59.22
- ASTH $29.08
- Analyst Decision
- PTGX Strong Buy
- ASTH Strong Buy
- Analyst Count
- PTGX 9
- ASTH 8
- Target Price
- PTGX $70.44
- ASTH $53.29
- AVG Volume (30 Days)
- PTGX 925.0K
- ASTH 333.2K
- Earning Date
- PTGX 11-06-2025
- ASTH 11-06-2025
- Dividend Yield
- PTGX N/A
- ASTH N/A
- EPS Growth
- PTGX N/A
- ASTH N/A
- EPS
- PTGX 0.80
- ASTH 0.52
- Revenue
- PTGX $209,180,000.00
- ASTH $2,419,115,000.00
- Revenue This Year
- PTGX N/A
- ASTH $60.77
- Revenue Next Year
- PTGX $248.17
- ASTH $26.90
- P/E Ratio
- PTGX $73.55
- ASTH $56.27
- Revenue Growth
- PTGX N/A
- ASTH 51.97
- 52 Week Low
- PTGX $33.31
- ASTH $21.20
- 52 Week High
- PTGX $61.89
- ASTH $63.20
- Technical
- Relative Strength Index (RSI)
- PTGX 55.46
- ASTH 49.52
- Support Level
- PTGX $57.90
- ASTH $28.48
- Resistance Level
- PTGX $60.40
- ASTH $30.58
- Average True Range (ATR)
- PTGX 2.52
- ASTH 1.21
- MACD
- PTGX -0.11
- ASTH -0.37
- Stochastic Oscillator
- PTGX 63.87
- ASTH 16.30
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About ASTH Astrana Health Inc. Common Stock
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.